AbbVie (ABBV) Stock Could Sit Below Fair Value While Earnings Look Rich

AbbVie stock has delivered a strong 163.4% total return over the past five years, while current valuation checks send a mixed message, with a Discounted Cash Flow (DCF) estimate pointing to a large discount to intrinsic value and market multiples suggesting the shares are expensive.

• Over five years, AbbVie has returned 163.4%, which places recent share price moves in the context of a long period of strong gains.
• Recent European approvals for Rinvoq in non segmental vitiligo and severe alopecia areata can support expectations for future cash flows, while the earnings impact of the planned Apogee Therapeutics acquisition and pipeline setbacks such as the epcoritamab trial outcome may influence how much investors are willing to pay for that growth.
• The stock screens as undervalued on a Discounted Cash Flow (DCF) basis with an estimated 45.9% discount to intrinsic value, yet equity checks are less supportive, with AbbVie only passing 2 of 6 valuation tests, which leans more toward expensive than a clear bargain.

The issue now is whether AbbVie’s current price better reflects the DCF style intrinsic value estimate or the richer picture implied by market multiples.

Find out why AbbVie's 32.5% return over the last year is lagging behind its peers.

Does AbbVie Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model values AbbVie based on the cash it is expected to generate for shareholders. For AbbVie, the model uses a 2 Stage Free Cash Flow to Equity approach built on recent cash generation of about $20.1b in free cash flow over the last twelve months and an outlook that assumes free cash flow continues to grow from that base.

Based on these projections, the DCF model arrives at an estimated intrinsic value of about $463.89 per share, which is 45.9% above the current share price. On this basis, AbbVie appears undervalued according to this method. The recent decision to lower full year profit guidance because of the planned Apogee Therapeutics acquisition helps explain why the market is currently pricing the stock below the value suggested by the cash flow model.

Overall, the DCF analysis indicates AbbVie stock appears undervalued relative to the cash flows analysts expect it to generate.

Our Discounted Cash Flow (DCF) analysis suggests AbbVie is undervalued by 45.9%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for AbbVie.

Does AbbVie Look Pricey on Earnings?

P/E is usually a useful yardstick for AbbVie because earnings are a core focus for many healthcare investors. On this metric, AbbVie trades on a P/E of 123.3x, which is far above the biotech industry average of 17.1x and also well ahead of the broader peer group average of 22.4x.

The fair P/E that adjusts for AbbVie’s size, sector and risk profile is estimated at 33.4x. The current multiple is therefore several times higher than what this model suggests. Because the gap is so wide, the fair ratio is better read as an indication that the stock screens very expensively on earnings rather than a precise target level.

On the P/E multiple, AbbVie stock currently screens as expensive relative to both peers and this tailored fair value benchmark.

See what the numbers say about this price — find out in our valuation breakdown.

The AbbVie Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where AbbVie’s valuation puzzle leaves off and show what kind of future growth, margins and earnings path would need to hold for the stock to be worth materially more or materially less than today’s price. Each narrative links its figures to a clear view of how AbbVie’s growth, profitability and risks might change over time. You can revisit these narratives on the Community page as new information emerges.

Be one of the first voices in the Simply Wall St community to set out a clear, number driven narrative on AbbVie that weighs developments like the Rinvoq approvals and the planned Apogee Therapeutics acquisition. Share your view on whether AbbVie’s current price makes sense given these shifts, and see how your thesis holds up as new results arrive.

Do you think there's more to the story for AbbVie? Head over to our Community to see what others are saying!

The Bottom Line

AbbVie sits at a crossroads where the Discounted Cash Flow (DCF) view suggests a clear intrinsic value upside, while the very high P/E multiple points to an overvalued stock on earnings. The weak broader valuation checks hint that the cash flow signal on its own may not tell the full story, especially with sentiment and comparable stocks heavily influencing the multiple. The wide gap between the two frameworks largely comes down to how confidently you view AbbVie’s future cash flows versus what you are willing to pay for those earnings today. The key question from here is whether future growth and margins ultimately justify the current rich multiple.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com